Biochemical Engineering Special Interest Group
biological engineering professionals
05 April 2017

Offering brings in $42M for Adaptimmune

Adaptimmune Therapeutics plc has raised US$42m through 7 million American Depositary Shares at US$6 each. Net proceeds of the offering will be used to advance the company’s wholly-owned pipeline of SPEAR T-cell candidates through clinical trials as well as for other general corporate purposes. The company said that, together with a public offering of US$66m of last week, it is now well-financed to develop its Spear T cell therapies until 2019. Source: European Biotechnology 6/4/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).